News | May 11, 2021
CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
The Government of India has started importing the vital drug Remdesivir from other countries to ease out the shortage of Remdesivir in the country
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
Acquisition of A&C expands Aceto’s Western manufacturing footprint
Subscribe To Our Newsletter & Stay Updated
